ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

10,115Medicare Part D Prescriptions Filled, Including Refills

Rank: 251 out of 939

$560K Total Retail Price of All Prescriptions

Rank: 196 out of 939

334 Patients Receiving at Least One Drug in Part D
42%Patients 65 Years and Older
76% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Arkansas
Lower avg

Schedule Two
Controlled Substances

9% of this provider’s 334 patients filled at least one prescription for a schedule two drug, compared to an average of 5%.

Schedule Three
Controlled Substances

21% of this provider’s 334 patients filled at least one prescription for a schedule three drug, compared to an average of 19%.

Risky Drugs to Seniors

2% of this provider’s 3,714 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 2%.

Brand Name Drugs

23% of this provider’s prescriptions were for brand-name drugs, compared to an average of 21%.

Prescription Price

$55 was the average price of a prescription from this provider, compared to $49 among peers.

Prescriptions per Patient

30 is the average number of prescriptions (including refills) per patient, compared to an average of 22.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Arkansas
LISINOPRIL 468 171 1 3
HYDROCODONE-ACETAMINOPHEN 463 109 S3 2 1
LEVOTHYROXINE SODIUM 380 133 3 4
OMEPRAZOLE 357 110 4 5
SIMVASTATIN 352 140 5 2
METFORMIN HCL 249 107 6 8
CARVEDILOL 236 124 7 25
AMLODIPINE BESYLATE 230 106 8 6
FUROSEMIDE 190 103 9 7
GABAPENTIN 189 84 10 11
MELOXICAM 183 79 11 14
ZOLPIDEM TARTRATE 180 50 12 20
NEXIUM 171 19 13 18
PROAIR HFA 148 26 14 41
POTASSIUM CHLORIDE 137 69 15 9
HYDROCHLOROTHIAZIDE 133 67 16 12
METOPROLOL SUCCINATE 124 79 17 21
ATORVASTATIN CALCIUM 123 42 18 22
FLUOXETINE HCL 120 24 19 47
ALENDRONATE SODIUM 118 75 20 40
METOPROLOL TARTRATE 117 45 21 10
ATENOLOL 108 38 22 19
PRAVASTATIN SODIUM 101 72 23 13
CYMBALTA 92 26 24 44
CITALOPRAM HBR 89 43 25 15
LYRICA 85 41 26 63
PROMETHAZINE HCL 84 0 R 27 68
GEMFIBROZIL 82 15 28 100
TRAMADOL HCL 81 30 29 16
CRESTOR 78 24 30 34
WARFARIN SODIUM 75 51 31 17
DONEPEZIL HCL 74 54 32 30
RANITIDINE HCL 68 34 33 35
GLIMEPIRIDE 66 24 34 37
LOSARTAN POTASSIUM 65 42 35 29
SERTRALINE HCL 63 16 36 24
CLOPIDOGREL 62 30 37 28
CHLORTHALIDONE 61 24 38 165
SPIRIVA 57 25 39 73
FENOFIBRATE 57 0 39 83
VENLAFAXINE HCL ER 57 18 39 121
VENTOLIN HFA 56 0 42 80
METOCLOPRAMIDE HCL 54 0 43 119
LEVEMIR FLEXPEN 53 20 44 190
MIRTAZAPINE 51 14 45 56
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Aug. 27, 2010.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.